P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS

• Zachary Zaroogian,
• Elżbieta Adamczyk,
• Adrianna Moszyńska,
• Marta Obacz,
• Urszula Pakulska,
• Benjamin Durham,
• Milena Mazan,
• Shoron Mowla,
• Katarzyna Wnęk,
• Amritha Varshini Hanasoge Somasundara,
• Beata Barczuk,
• Aniela Gołas,
• Ross Levine,
• Tomasz Rzymski,
• Raajit K Rampal

Affiliations

Zachary Zaroogian

1 Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States

Elżbieta Adamczyk

2 Ryvu Therapeutics, Kraków, Poland

Adrianna Moszyńska

2 Ryvu Therapeutics, Kraków, Poland

Marta Obacz

2 Ryvu Therapeutics, Kraków, Poland

Urszula Pakulska

2 Ryvu Therapeutics, Kraków, Poland

Benjamin Durham

1 Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States

Milena Mazan

2 Ryvu Therapeutics, Kraków, Poland

Shoron Mowla

1 Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States

Katarzyna Wnęk

2 Ryvu Therapeutics, Kraków, Poland

Amritha Varshini Hanasoge Somasundara

1 Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States

Beata Barczuk

2 Ryvu Therapeutics, Kraków, Poland

Aniela Gołas

2 Ryvu Therapeutics, Kraków, Poland

Ross Levine

1 Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States

Tomasz Rzymski

2 Ryvu Therapeutics, Kraków, Poland

Raajit K Rampal

1 Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States